Metronidazole pessaries compared with placebo in the treatment of bacterial vaginosis.

Abstract

In a randomized, double-blind clinical trial from general practice, 500 mg metronidazole pessaries applied once daily for seven days were compared with placebo in the treatment of bacterial vaginosis. Seventy-five women completed the study. At the follow-up visit immediately after completion of treatment, none of the patients on metronidazole fulfilled the criteria for bacterial vaginosis, compared with 12 (35%) in the placebo group (p less than 0.001). Nine (22%) of the patients treated with metronidazole harboured Gardnerella vaginalis after treatments, compared with 31 (91%) in the placebo group (p less than 0.001). Symptoms had improved or disappeared in 33 (80%) on metronidazole, and in 18 (53%) on placebo therapy (p less than 0.05). Four weeks after the follow-up visit, symptoms were reported by 28% in the metronidazole group and by 44% in the placebo group (p greater than 0.05). Metronidazole pessaries are effective in the treatment of bacterial vaginosis.

• Authors: F Bro
• Journal: Scandinavian journal of primary health care (Scand J Prim Health Care) Vol. 8 Issue 4 Pg. 219-23 (Dec 1990) ISSN: 0281-3432 [Print] United States
• PMID: 2284521 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Placebos
• Metronidazole

Topics

• Adult
• Candidiasis, Vulvovaginal (drug therapy)
• Double-Blind Method
• Family Practice
• Female
• Gardnerella vaginalis (isolation & purification)
• Haemophilus Infections (drug therapy, microbiology)
• Humans
• Metronidazole (administration & dosage, therapeutic use)
• Pessaries
• Placebos
• Vaginitis (diagnosis, drug therapy)